The present disclosure provides methadone prodrugs, pharmaceutical compositions thereof, and such prodrugs methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, utilized for the treatment or prevention of pain, as well as methods for administering to a subject such prodrugs.
C07C 279/12 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
Compositions and methods that can be used to treat or prevent a viral infection are described herein. For example, pharmaceutical compositions containing nafamostat mesylate may be used to treat infection by SARS-CoV-2 (“COVID-19”). Oral administration of nafamostat mesylate may be effective to reduce viral load in the gastrointestinal tract and reduce related GI symptoms.
The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
C07C 279/12 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
C07C 271/10 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
5.
MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME
Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described.
Aspects of the present disclosure include pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions include an active agent prodrug that provides enzymatically-controlled release of an active agent, and controlled release nafamostat or a pharmaceutically acceptable salt thereof.
Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described.
Aspects of the present disclosure include pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions include an active agent prodrug that provides enzymatically-controlled release of an active agent, and controlled release nafamostat or a pharmaceutically acceptable salt thereof.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
9.
COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF
The embodiments provide Compound AM-9, Amphetamine-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof and Compound AM-10, Amphetamine-arginine-alanine-acetate. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound AM-9 or Compound AM-10, that provides controlled release of amphetamine Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of amphetamine from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
10.
METHODS FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT
Compositions and methods that can be used to treat or prevent a viral infection are described herein. For example, pharmaceutical compositions containing nafamostat mesylate may be used to treat infection by SARS-CoV-2 ("COVID-19"). Oral administration of nafamostat mesylate may be effective to reduce viral load in the gastrointestinal tract and reduce related GI symptoms.
The embodiments provide Compound AM-9, Amphetamine-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof and Compound AM-10, Amphetamine-arginine-alanine-acetate. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound AM-9 or Compound AM-10, that provides controlled release of amphetamine. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of amphetamine from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, drug precursors, administered in a variety of forms and through various routes, that function as drug delivery agents to provide controlled release of active ingredients for a wide variety of pharmaceuticals, resulting in benefits such as a modified PK profile, tamper resistance, abuse resistance and overdose protection
13.
Single walled carbon nanotube/sirna complexes and methods related thereto
The present invention includes single-walled carbon nanotube compositions for the delivery of bioactive agents and methods of making such single-walled carbon nanotube compositions.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
14.
SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO
The present invention includes single-walled carbon nanotube compositions for the delivery of bioactive agents and methods of making such single-walled carbon nanotube compositions.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
The present invention includes fullerene carbon nanotube compositions complexed with multiple bioactive agents and methods related to such fullerene carbon nanotube compositions.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is associated with the carbon nanotubes.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
